Generic Name and Formulations:
Desonide 0.05%; crm.
Encore Dermatology, Inc.
Indications for TRIDESILON:
Apply thin film 2–4 times daily. Do not occlude. Reevaluate if no improvement after 2 weeks.
Treat infection if present or develop; discontinue until infection controlled. Systemic absorption increased by altered skin barrier, inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Do not use near eyes, or if hypersensitivity to corticosteroid, or pre-existing skin atrophy. Allergic contact dermatitis. Pregnancy (Cat.C). Nursing mothers.
Pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, burning, hypergylcemia, liver function abnormality; HPA axis suppression (esp. in children).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline